This page contains a Flash digital edition of a book.
1. Lossos I.S., Morgensztern D. Prognostic Biomarkers in Diffuse Large a clinicopathologic analysis of cases included in the German BFM (Ber-
B-Cell Lymphoma, J Clin Oncol, 2006;24(6):995-1007.
lin-Frankfurt-Munster) Multicenter Trial. Blood 2006; 107: 4047-4052.
2. De Paepe P., De Wolf Peeters C. Diffuse large B-cell lymphoma: a het-
21. Biasoli I., Morais J.C., Scheliga A., Milito C.B., Romano S., Land M. et
erogenous group of non-Hodgkin Lymphomas comprising several dis-
al. CD10 and bcl2 expression combined with International Prognos-
tinct clinicopatjological entities, Leukemia, 2007;21:37-43.
3. Gatter K.C., Warnke R.A. Diffuse large B-cell lymphoma. In: Jaffe E.S.,
tic Index can identify subgroups of patients with diffuse large B-cell
Harris N.L., Stein H., Vardiman J.W. (eds). World Health Organization
lymphoma with very good and very poor prognosis, Histopathology,
Classification of Tumours. Pathology and Genetics of Tumours of Hae-
matopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001:171-174. 22. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie
4. Atkins C.D. A predictive model for non-Hodgkin’s lymphoma. N Engl J
J., Ott G. et al. Confirmation of the molecular classification of diffuse
Med 1994; 330:574-575.
large B-cell lymphoma by immunohistochemistry using a tissue mi-
5. Bea S., Zettle A., Wright G., Salaverria I., Jehn P. Diffuse large B-cell
croarray, Blood 2004;103:275-282.
lymphoma subgroups have distinct genetic profiles that influence tu-
mor biology and improve gene-expression-based survival prediction,
23. Nyman H., Adde M., Karjalainen-Lindsberg M.L., Taskinen M.,
Blood, 2005;106:3183-3190.
Berglund M., Amini R.M. et al. Prognostic Impact of Immunohisto-
6. Hedvat C., Hegde A., Chaganti R. Application of tissue microarray tech-
chemically Defined Germinal Centre Phenotype in Diffuse Large B
nology to the study of non-Hodgkin’s and Hodgkin’s lymphoma, Hum Cell Lymphoma Patients Treated with Immunochemotherapy, Blood,
Pathol 2002;33:968-974.
2007;prepublished online; DOI 10.1182/blood_2006-09-047068.
7. Tzankov A., Pehrs A.C., Zimpfer A., Asconi S., Lugli A., Pilieri S. et al.
24. Moskowity C.H., Zelenetz A.D., Kewalramani T. Cells of origin, ger-
Prognostic significance of CD44 expression in diffuse large B-cell lym-
minated center versus nongerminal center, determined by immuno-
phoma of activated and germinal centre B cell like types: a tissue mi-
croarray analysis of 90 cases, J Clin Pathol, 2003;56:747-752.
hystochemistry on tissue microarray does not correlate with outcome
8. Murris J.J., Meijer C.J., Vos W., van Krieken J.H., Jiwa N.M., Ossenkap-
in patients with relapsed and refractory DLBCL, Blood, 2005;106:3383-
pelle G.J. et al. Immunohistochemical profiling based on bcl2, CD10
and MUM1 expression improves risk stratification in patients with pri- 25. Jazirehi A.R., Bonavida B. Cellular and molecular signal transduction
mary nodal diffuse large B-cell lymphoma, J Pathol, 2006;208:714-723.
pathways modulated by rituximab (rituxan, anti CD20 mAb) in non
9. Wilson W.H., Teruya-Feldstein J., Fest T., Harris C., Steinberg S.M. et al.
Hodgkin’s lymphoma: implications in chemosensitisation anf thera-
Relation of p53, bcl2 and tumor proliferation to clinical drug resiseance
peutic intervention, Oncogene, 2005;24:2121-2143.
in non Hodgkin’s lymphomas, Blood,1997;89(2):601-609.
10. Stauder R., Eistrer W., Thaler J., Gunthert U. CD44 variant izoforms
26. Farinha P., Sehn L.H., Skinnider B.K., Connors J.M., Gascoyne R.D. Ad-
in non Hodkin’s lymphoma: a new independent prognostic factor,
dition of Rituximab to CHOP improves survival in the non-GCB sub-
type of diffuse large B-cell lymphoma (DLBCL), Blood,2006:816a.
11. Gafford J.T., Skidgel R.A., Erdos E.G. Human „kidney enkephalinase” a 27. Saito B., Shiozawa E., Usui T. Treatment effect of Rituxiamb plus che-
neutral metalloendopeptidase that cleaves active peptides, Biochem-
motherapy is obtained by improving survival from non germinal cen-
istry, 1983;22:3265-3271.
ter type untreated diffuse large B-cell lymphoma, Blood;2006:2032a.
12. Ohshima K., Kawasaki C., Muta C., Mutak K., Deyev V., Haraoko S. et
28. Kerbauy F.R., Colleoni G.W., Saad S.T. Detection and possible prog-
al. CD10 and bcl10 expression in diffuse large B-cell lymphoma. CD10
is a marker of improved prognosis, Histopathology, 2002;39:156-162.
nostic relevance of p53 mutation in diffuse large B-cell lymphoma.
13. Huang J.Z., Sanger W.G., Greiner T.C., Staudt L.M., Weisenburger D.D.,
An analysis of 51 cases and rewiew of the literature, Leuk Lymphoma,
Pickering D.L. et al. The t(14;18) defines a unique subset of diffuse large
B-cell lymphoma with a germinal center B-cell gene expression profile, 29. Grogan T.M., Lippman S.M., Spier C.M., Llymen D.J., Rybski J.A., Ran-
Blood, 2002;99:2285-2890.
gel C.S. et al. Independent prognostic significance of nuclear prolifera-
14. Barrans S.L., Carter I., Owen R.G., Davies F.E., Patmore R.D., Haynes
tion antigen in diffuse large B-cell lymphomas as determined by the
A.P. et al. Germinal center phenotype and bcl2 expression combined
monoclonal antibody Ki67, Blood, 1988;71(4):1578-1160.
with the International Prognostic Index improves patient risk stratifi-
cation in diffuse large B-cell lymphoma, Blood, 2002;99:1136-1143.
30. Veelken H., Dennheim S.V., Moenting J.S., Martens U.M., Finke J.,
15. Winter J.N., Weller E.A., Horning S.J., Krajewska M., Variakojis K.,
Schmitt-Graeff A. Immunophenotype as prognostic factor for diffuse
Habermann T.M. et al. Prognostic significance of bcl6 protein expres-
B-cell lymphoma in patients undergoing clinical risk-adapted therapy,
sion in diffuse large B-cell lymphomas treated with CHOP or R-CHOP: Ann Oncol. 2007;18(5):931-9.
a prospective correlative study, Blood, 2006;107(11):4207-4213.
31. Sugahara K.N., Hirata T., Nayasaka H. Tumor cells enhance their own
16. Iqbal J., Neppalli V.B.T., Wright G., Dave B.J., Horsman D.E., Rosenwald
CD44 cleavage and motility by generating hyaluronan fragments, J Biol
A. et al. Bcl2 expression is a prognostic marker for the activated B-cell
Chem, 2006;281(9):5861-5868.
lymphoma, J Clin Oncol, 2006;24:961-968.
17. Shivakumar L., Armitage J.O. Bcl2 gene expression as a predictor of
32. Tzircotis G., Thorne R.F., Isacke C.M. Chemotaxis toward hyaluronan
outcome in diffuse large B-cell lymphoma, Clin Lymphoma Myeloma,
is dependent on CD44 expression and modulated by cell type variation
in CD44 hyaluronan binding, J Cell Sci, 2005;118(21):5119-5128.
18. Sehn L.H. Optimal Use of Prognostic Factors in Non Hodgkin Lym- 33. Marhaba R., Zoller M. CD44 in cancer progression: adhesion, migra-
phoma; Hematology 2006, American Society of Hematology, Educa-
tion and growth regulation, J Mol Histol, 2004;35(3):211-231.
tional Program Book:2-8.
34. Jothy S. CD44 and its partners in metastasis, Clin Exp Metastasis,
19. Rosenwald A., Wright G., Chan W.C. The use of molecular profiling to
predict survival after chemotherapy for diffuse large B-cell lymphoma,
N Engl J Med, 2002;346:1937-1947.
35. Drillenburg P., Wielenga V.J., Kramer M.H., van Krieken J.H., Kluin-
20. Oschlies I., Klapper W., Zimmermann M., Krams M., Wacker H.H.,
Nelemans H.C., Hermans J. et al. CD44 expression predicts disease out-
Burkhardt B. et al. Diffuse large B-cell lymphoma in pediatric patients
come in localiyed large B-cell lymphoma, Leukemia, 1999;13(9):1448-
belongs predominantly to the germinal-center type B-cell lymphomas: 1455.
pag. 42
Nr. 7 (2)/2009
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68
Produced with Yudu -